

## PRECISION AND FUTURE MEDICINE

Potential relationship between GLP-1 RAs and suicide risk

**Supplementary Table 5.** Two-by-two contingency table

Category	AEs of suicide/self-injury	All other AEs
GLP-1 RA	A	B
Comparative drugs	C	D

AE, adverse event; GLP-1 RA, glucagon-like peptide-1 receptor agonist.

**Supplementary Table 6.** Disproportionality analysis of suicide/self-injury cases by liraglutide dose

Drug	Dose (mg)	No. of cases	No. of non-cases	Compared with all other drugs		Compared with orlistat	
				ROR (95% CI)	IC <sub>025</sub>	ROR (95% CI)	IC <sub>025</sub>
Liraglutide	0.6	23	17,166	0.32 (0.22–0.49)	–2.14	1.93 (1.14–3.24)	0.01
	1.2	16	14,196	0.27 (0.17–0.45)	–2.47	1.62 (0.90–2.91)	–0.21
	1.8	12	14,540	0.20 (0.11–0.35)	–2.99	1.19 (0.62–2.28)	–0.60
	2.4 <sup>a)</sup>	0	2,555	-	-	-	-
	3 <sup>a)</sup>	6	7,563	0.19 (0.09–0.43)	–3.22	1.14 (0.48–2.70)	–0.80

ROR, reporting odds ratio; CI, confidence interval; IC, information component.

<sup>a)</sup>Only for weight loss.